Merck & Co., Inc. Derivative Liability
Merck & Co., Inc. (MRK) had Derivative Liability of $252.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-07
- 2026-06-30: Derivative Liability $252.00M.
- 2026-03-31: Derivative Liability $229.00M.
- 2025-12-31: Derivative Liability $324.00M.
- 2025-09-30: Derivative Liability $492.00M.
| Period end | Derivative Liability |
|---|---|
| 2026-06-30 | $252.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $229.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $324.00M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $492.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $855.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $268.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $345.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $298.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $142.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $167.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $239.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $176.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $244.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $284.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $409.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | $242.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $134.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $241.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $121.00M 10-K · filed 2023-02-24 |
| 2021-09-30 | $133.00M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $174.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $281.00M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $525.00M 10-K · filed 2022-02-25 |
| 2020-09-30 | $298.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $131.00M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $93.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $97.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $110.00M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $84.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $195.00M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $160.00M 10-K · filed 2020-02-26 |
| 2018-09-30 | $204.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $197.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $324.00M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $217.00M 10-K · filed 2019-02-27 |
| 2017-09-30 | $227.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $201.00M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $146.00M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $134.00M 10-K · filed 2018-02-27 |
| 2016-09-30 | $57.00M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $71.00M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $164.00M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $63.00M 10-K · filed 2017-02-28 |
| 2015-09-30 | $56.00M 10-Q · filed 2015-11-05 |
| 2014-12-31 | $103.00M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |